NCT07513844 · RECRUITING
Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
This trial is testing a non-invasive brain stimulation device called low-intensity focused ultrasound, or LIFU, aimed at a deep brain region called the globus pallidus. The goal is to find the right settings to safely reduce the involuntary movements, called chorea, that are a hallmark of Huntington's disease. This is a Phase NA study, meaning it is an early-stage parameter-optimization experiment, not yet a full efficacy trial.
You may qualify if
- Aged 18 to 75 years (inclusive)
- Genetically confirmed Huntington's disease with HTT CAG repeat length of 40 or greater
- Unified Huntington's Disease Rating Scale Total Maximal Chorea score of 8 or higher on a scale of 0 to 28, with higher scores indicating more severe chorea
- Huntington's Disease Integrated Staging System stage 2 or 3
- Willing to participate and provide informed consent
- Have a reliable caregiver available
- No severe cognitive impairment that would preclude reliable reporting of adverse events or efficacy during treatment
You're excluded if
- History of self-injury, aggressive behavior, or unstable psychiatric disorders
- History of head injury or neurosurgical procedure
- Presence of intracranial implants, metallic foreign bodies, cochlear implants, or cardiac pacemakers
- Severe systemic disease, pregnancy, or breastfeeding
- Contraindications to magnetic resonance imaging, ultrasound, or anesthesia
- Prior treatment with electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, transcranial alternating current stimulation, or other neuromodulation therapies within the past 3 years
- Severe brain atrophy with unclear external globus pallidus structure on MRI
- Concurrent participation in another interventional clinical trial
- Any other condition that, in the opinion of the investigator, would preclude participation
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-29